Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are the most heavily discussed drugs of the decade, and much of the discussion has drifted from weight to the mind: users describe a sudden silence where constant thoughts about food used to be, and some also describe feeling flat, tired or foggy. The weight-loss evidence is unusually strong. The brain evidence is a different story: some of it is solid, some of it is emerging, and a lot of it simply does not exist yet. This article separates the three.
A note before the evidence: nothing here is individual medical advice. Decisions about starting, stopping or dosing these drugs belong with you and a prescriber.
What these drugs are, and why the brain is involved at all
Semaglutide is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a gut hormone released after eating. Tirzepatide adds agonism at a second receptor, GIP. In the pivotal STEP 1 trial, researchers enrolled 1,961 adults without diabetes and randomised them to weekly semaglutide 2.4 mg or placebo for 68 weeks; the semaglutide group lost 14.9% of body weight against 2.4% on placebo. In SURMOUNT-1, 2,539 adults were assigned to tirzepatide 5, 10 or 15 mg or placebo for 72 weeks, with substantial, dose-dependent weight loss.
The brain connection is not speculative. GLP-1 receptors are expressed widely in the central nervous system, including the hypothalamus (energy balance), hippocampus (memory), brainstem and cortex. That receptor map is why these drugs change appetite at all, and it is also why researchers are asking what else they might change.
What “food noise” means
“Food noise” is a patient-coined term, not a diagnosis. Researchers who have tried to formalise it describe heightened food cue reactivity: intrusive, repetitive thoughts about food that persist between meals and are experienced as unwanted. A 2023 narrative review in Nutrients set out to define the term and link it to the better-studied construct of food cue reactivity, and proposed a formal model for studying it.
The claim that GLP-1 drugs reduce food noise currently rests on three kinds of evidence, in descending order of strength. First, the drugs’ effect on appetite and eating behaviour is well established from the trials above. Second, there is mechanistic support: functional MRI studies show that GLP-1 receptor agonists such as liraglutide modulate brain responses to palatable food cues, which is a plausible physiological basis for quieter food thoughts. Third, and weakest, there are widespread but unsystematic patient and clinician reports. What does not yet exist is a large randomised trial with food noise itself as a pre-specified, validated outcome measure. The reduction is probably real for many people, given how consistently it is reported and how well it fits the mechanism, but its size, duration and who gets it have not been quantified properly.
Fatigue and low energy: a documented side effect
Tiredness on these drugs is not imagined. Fatigue appears on the US prescribing information for Wegovy among the most common adverse reactions, alongside nausea, headache and the gastrointestinal effects. Gastrointestinal symptoms dominate the adverse-event tables: in pooled data from the STEP 1 to 3 trials, nausea affected 43.9% of semaglutide participants versus 16.1% on placebo.
Why fatigue happens is less settled. Candidate explanations include the large drop in calorie intake, dehydration from nausea or vomiting, disrupted sleep from gastrointestinal symptoms, and possibly central effects of the drug itself. The trials were not designed to separate these. What the trial pattern does suggest is that most side effects cluster around dose escalation and ease over time, though fatigue was occasionally severe enough to end participation: in the STEP 7 trial, one discontinuation in the semaglutide group was attributed to fatigue.
If you are on one of these drugs and running on fumes, the mundane checks (total calories, protein, fluids, sleep) are worth doing before assuming the drug itself is the sole cause, and persistent or severe fatigue is a conversation for your prescriber, not a forum.
Concentration, memory and mood: mostly unknown
This is where marketing and anecdote outrun the data furthest, in both directions. Some users report better focus once food noise quiets; others report brain fog.
The honest summary is that GLP-1 receptor agonists are being actively studied for brain outcomes, largely in the context of neurodegenerative disease, and the clinical results so far are mixed. Preclinical work shows neuroprotective mechanisms, but a 2025 review of GLP-1 drugs in neurological disorders puts it plainly: some trials show modest improvements in cognition or motor function, others show no meaningful effect. A separate 2025 review of GLP-1s and food-related cognition concludes that the human data are preliminary, indirect and drawn mainly from small, heterogeneous studies.
For the specific question a desk worker actually cares about (will this drug make me sharper or duller at work over the next year?), there is no adequately powered randomised evidence either way. The large obesity trials did not measure cognition as an outcome. Mood is monitored on the safety side (the Wegovy label carries a precaution about depression and suicidal ideation, and users are told to report mood changes), but that is safety surveillance, not evidence of a typical effect.
The practical takeaway
Well evidenced: large weight loss, strong effects on appetite and eating behaviour, gastrointestinal side effects, and fatigue as a recognised common adverse reaction. Emerging: reduced food cue reactivity in the brain, consistent with the food noise reports. Not established: effects on concentration, memory or day-to-day mood, in either direction. Anyone selling you “Ozempic brain” as either a superpower or a syndrome is ahead of the literature.
Common questions
What is food noise?
Food noise is an informal term for intrusive, repetitive, unwanted thoughts about food that persist between meals. Researchers link it to food cue reactivity, the brain’s response to food cues, rather than treating it as a diagnosis. It became widely discussed because many GLP-1 users report it vanishing on treatment.
Do Ozempic and Wegovy really stop food noise?
Many users and clinicians report exactly that, and brain-imaging studies showing GLP-1 drugs dampen responses to food cues make it biologically plausible. What is missing is a large randomised trial measuring food noise directly, so the size and reliability of the effect are not established.
Why do GLP-1 drugs make you tired?
Fatigue is listed among the most common adverse reactions in Wegovy’s prescribing information, but the mechanism is not settled. Eating far fewer calories, dehydration from nausea, and disturbed sleep from gastrointestinal side effects are all plausible contributors. Persistent fatigue is worth raising with your prescriber.
Does semaglutide affect memory or concentration?
Nobody knows yet. The big obesity trials did not measure cognition, and studies of GLP-1 drugs on the brain (mostly in neurodegenerative disease) show mixed results: modest improvements in some trials, no meaningful effect in others. Claims in either direction are ahead of the evidence.
The bottom line
If you take a GLP-1 drug, expect strong effects on appetite and weight, expect gastrointestinal side effects, and treat fatigue as a real, documented possibility with several fixable contributors. Treat quieter food noise as a likely but not yet quantified benefit. Do not start or continue one of these drugs for cognitive effects: that evidence does not exist yet.
Did this answer your question?
Thanks. That helps us decide what to fix.
Leave a comment